GT Biopharma (GTBP)
NASDAQ:GTBP
Want to see GTBP full AI Analyst Report?
Top Page
GT Biopharma
(NASDAQ:GTBP)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.43
▼(-41.23% Downside)
Action:ReiteratedDate:04/08/26
The score is primarily constrained by weak financial performance (no revenue, heavy losses, and sustained cash burn), with technicals also reflecting a weak longer-term trend. A constructive clinical-trial partnership provides some offset, but negative earnings and lack of dividend support keep the valuation component low.
Positive Factors
Low leverage / minimal debt
A near-zero debt profile is a durable financial strength for a pre-commercial biotech. It reduces insolvency risk, preserves flexibility to raise equity or fund trials, and limits fixed obligations, giving management more runway to prioritize clinical milestones over interest pressures.
Negative Factors
No revenue & sustained cash burn
Persistent negative operating and free cash flow without product revenues creates ongoing funding dependence. Over the next 2-6 months this structural cash burn raises dilution and financing risk, constrains discretionary R&D, and could force reprioritization of programs absent new capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / minimal debt
A near-zero debt profile is a durable financial strength for a pre-commercial biotech. It reduces insolvency risk, preserves flexibility to raise equity or fund trials, and limits fixed obligations, giving management more runway to prioritize clinical milestones over interest pressures.
Read all positive factors
GT Biopharma (GTBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.24M
Dividend YieldN/A
Average Volume (3M)1.63M
Price to Earnings (P/E)―
Beta (1Y)0.39
Revenue GrowthN/A
EPS Growth54.62%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.22
Shares Outstanding31,553,892
10 Day Avg. Volume1,818,785
30 Day Avg. Volume1,629,462
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap-0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.08
Forecast
1Y Price Target
$3.00Price Target Upside310.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.7
Revenue Forecast (FY)N/A
GT Biopharma Business Overview & Revenue Model
Company Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology...
How the Company Makes Money
null...
GT Biopharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -34.32M | -13.16M | 5.98M | -20.96M | -57.48M |
| Net Income | -28.35M | -13.16M | -7.60M | -20.88M | -58.01M |
Balance Sheet | |||||
| Total Assets | 8.11M | 4.23M | 14.11M | 16.74M | 32.17M |
| Cash, Cash Equivalents and Short-Term Investments | 6.81M | 3.95M | 13.97M | 16.51M | 31.98M |
| Total Debt | 0.00 | 0.00 | 58.00K | 174.00K | 31.00K |
| Total Liabilities | 2.32M | 5.90M | 6.63M | 5.00M | 10.26M |
| Stockholders Equity | 5.79M | -1.67M | 7.48M | 11.73M | 21.91M |
Cash Flow | |||||
| Free Cash Flow | -12.91M | -12.90M | -8.85M | -15.22M | -15.61M |
| Operating Cash Flow | -12.91M | -12.90M | -8.85M | -15.22M | -15.61M |
| Investing Cash Flow | 0.00 | 12.89M | -2.01M | 12.14M | -23.04M |
| Financing Cash Flow | 15.78M | 2.98M | 6.27M | -224.00K | 42.32M |
GT Biopharma Technical Analysis
Negative
0.73
Price Trends
0.44
Negative
0.58
Negative
0.88
Negative
Market Momentum
-0.02
Positive
38.87
Neutral
38.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GTBP, the sentiment is Negative. The current price of 0.73 is above the 20-day moving average (MA) of 0.42, above the 50-day MA of 0.44, and below the 200-day MA of 0.88, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 38.87 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GTBP.
GT Biopharma Risk Analysis
GT Biopharma disclosed 60 risk factors in its most recent earnings report. GT Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GT Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $11.71M | -0.10 | -209.36% | ― | ― | 83.25% | |
44 Neutral | $5.07M | -0.28 | -203.36% | ― | ― | 90.53% | |
43 Neutral | $12.24M | -0.15 | -356.99% | ― | ― | 54.62% | |
43 Neutral | $3.56M | -0.12 | -215.04% | ― | -100.00% | 93.82% | |
42 Neutral | $4.69M | -0.22 | -0.40% | ― | ― | 96.26% |
* Healthcare Sector Average
GTBP
GT Biopharma
0.38
-1.79
-82.53%
TOVX
Theriva Biologics
0.26
-1.05
-80.38%
REVB
Revelation Biosciences
1.15
-36.57
-96.96%
DRMA
Dermata Therapeutics
1.36
-5.71
-80.76%
CERO
CERo Therapeutics Holdings
0.03
-12.74
-99.77%
AZTR
Azitra Inc
0.21
-1.78
-89.26%
GT Biopharma Corporate Events
Business Operations and Strategy
GT Biopharma Advances GTB-5550 via University Trial Pact
Positive
Apr 7, 2026
On April 3, 2026, GT Biopharma, Inc. entered into an Investigator Initiated Clinical Trial Agreement with the Regents of the University of Minnesota, under which the university will sponsor an IND application and act as sponsor investigator for a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.